{"id":511001,"date":"2021-07-08T10:06:57","date_gmt":"2021-07-08T14:06:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/"},"modified":"2021-07-08T10:06:57","modified_gmt":"2021-07-08T14:06:57","slug":"iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/","title":{"rendered":"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass. and GOSSELIES, Belgium, July  08, 2021  (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming William Blair Biotech Focus Conference 2021 titled: \u201cDeveloping Therapies for the Next IO Targets\u201d on Wednesday, July 14, 2021 at 2:10 p.m. ET.<\/p>\n<p>A live webcast of the presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.<\/p>\n<p>\n        <strong>About iTeos Therapeutics, Inc.<\/strong><br \/>\n        <br \/>iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company\u2019s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1\/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.<\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Ryan Baker<br \/>iTeos Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jk5NVwqyGDy5MI98b-3VGSTiCb4aoir_VMdcU5xMwsbUnQNGxalxFN_NNAeDozR1y-tXPtwzqrclPRyW4_X0Jh5wUq5Aa62YRaXBA6SKi_v1lzYs6VI2hiRVsiH6XF_P\" rel=\"nofollow noopener\" target=\"_blank\">Ryan.Baker@iteostherapeutics.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QOJ17ZiSgbOBX7F1ORmJfbARmtGDqWxjiKK-5jrUzoHSvooayBePxRoLQbYHr9ASZRAViLN7TT0zU_LvShksvQAqqpD8flr0kM_x_e4hWxMbZ11lmj5PHgJLsmZ1XB4j\" rel=\"nofollow noopener\" target=\"_blank\">media@iteostherapeutics.com<\/a>\n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ced7754c-359d-4ef4-b738-9370799d23ed\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming William Blair Biotech Focus Conference 2021 titled: \u201cDeveloping Therapies for the Next IO Targets\u201d on Wednesday, July 14, 2021 at 2:10 p.m. ET. A live webcast of the presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511001","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming William Blair Biotech Focus Conference 2021 titled: \u201cDeveloping Therapies for the Next IO Targets\u201d on Wednesday, July 14, 2021 at 2:10 p.m. ET. A live webcast of the presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage &hellip; Continue reading &quot;iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-08T14:06:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021\",\"datePublished\":\"2021-07-08T14:06:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/\"},\"wordCount\":313,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/\",\"name\":\"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=\",\"datePublished\":\"2021-07-08T14:06:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 - Market Newsdesk","og_description":"CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) &#8212; iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming William Blair Biotech Focus Conference 2021 titled: \u201cDeveloping Therapies for the Next IO Targets\u201d on Wednesday, July 14, 2021 at 2:10 p.m. ET. A live webcast of the presentation will be available on the Investors section of the company\u2019s website at https:\/\/www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage &hellip; Continue reading \"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-08T14:06:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021","datePublished":"2021-07-08T14:06:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/"},"wordCount":313,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/","name":"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=","datePublished":"2021-07-08T14:06:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NzQ0NyM0Mjg4NzcxIzIyMDA1NjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iteos-therapeutics-to-present-at-william-blair-biotech-focus-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511001"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}